NCT07112287View on ClinicalTrials.gov

Germline Testing for Predisposition to Myeloid Malignancies

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2033

Conditions
Myeloid MalignancyGenetic Predisposition to DiseaseMyeloid Hematological Malignancies
Interventions
DEVICE

MyeloGen Gene Panel

The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Broad Institute of MIT and Harvard

OTHER

lead

Christopher Reilly

OTHER